Lung Cancer
Conditions
Interventions
Experimental group:Tirelizumab combined with chemotherapy induction therapy + concurrent chemoradiotherapy + tirelizumab
Sponsors
Xiamen Humanity Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The patients voluntarily joined the study and signed the informed consent; 2. Patients aged >=18 years, no gender limit; 3. Histologically or cytologically confirmed, untreated, inoperable stage IIIA, IIIB, or IIIC non-small cell lung cancer Stage 8 with at least one measurable lesion (according to RECIST v1.1 criteria); 4. Normal organ function; 5. Forced expiratory volume in the first second (FEV1) is greater than 50% of the expected normal value; 6. The diffusion capacity of carbon monoxide lung exceeds 40% of the expected normal value; 7. Cytological or histological tumor tissue specimens can be provided; 8. Whole body positron emission tomography, computed tomography, high diagnostic quality computed tomography and brain imaging showed no evidence of metastatic lesions; 9. ECOG score: 0-1; 10. The major organs are functioning normally.
Exclusion criteria
Exclusion criteria: 1. Past receipt of antibodies or drugs targeting the immune checkpoint pathway, including but not limited to anti-PD-1, anti-PD-L1, or anti-cytotoxic T lymphocyte-associated antigen 4(anti-CTLA-4) antibodies; 2. Treatment with systemic immunomodulators (including but not limited to interferon, interleukin 2, tumor necrosis factor) within the first 4 weeks of enrollment or within the 5 half-lives of the drug, whichever is older (cancer vaccines are allowed in previous treatment); 3. Patients with known positive driver genes such as EGFR and ALK; 4. Medical history and complications: The patient was enrolled in another clinical study, had received chemotherapy, radiation, or other antitumor agents within 4 weeks prior to the first dose of the investigational drug, had an active known or suspected autoimmune disease, had severe cardiovascular disease, had a history of interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic disease, and had a known history of severe hypersensitivity to other monoclonal antibodies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year progression-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 year overall survival rate;Objective response rate; | — |
Countries
China
Contacts
Public ContactHuang Cheng
Outcome results
None listed